Association of osteopontin polymorphism with cancer risk: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 11, 2015, Pages 20911-20917

  Yang, Gang ^a   Peng, Xiaoxing ^a   Guo, Pengju ^a   Yang, Ge ^a  

^a CHANGCHUN UNIVERSITY   (China)

Author keywords

Gene; Meta; Osteopontin; Polymorphism; Risk; Tumor

Indexed keywords

OSTEOPONTIN;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER RISK; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INFORMATION PROCESSING; META ANALYSIS; OSTEOPONTIN GENE; QUALITY CONTROL; WEB OF SCIENCE;

EID: 84954224159     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D. Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol 2009; 24: 37-41.
2. Kim EK, Jeon I, Seo H, Park YJ, Song B, Lee KA, Jang Y, Chung Y, Kang CY. Tumor-derived osteopontin suppresses anti-tumor immunity by promoting extramedullary myelopoiesis. Cancer Res 2014; 74: 6705-6716.
3. Sun L, Pan J, Peng L, Fang L, Zhao X, Sun L, Yang Z, Ran Y. Combination of haptoglobin and osteopontin could predict colorectal cancer hepatic metastasis. Ann Surg Oncol 2012; 19: 2411-2419.
4. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012; 55: 483-490.
5. Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res 2012; 31: 26-37.
6. Beausoleil MS, Schulze EB, Goodale D, Postenka CO, Allan AL. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer 2011; 11: 25-36.
7. Zhao M, Xu H, Liang F, He J, Zhang J. Association of osteopontin expression with the prognosis of glioma patient: a meta-analysis. Tumour Biol 2014; 36: 429-436.
8. Wang YD, Chen H, Liu HQ, Hao M. Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis. Tumour Biol 2014; 35: 11799-11808.
9. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2007; 56: 782-789.
10. Lee TY, Lin JT, Wu CC, Yu CC, Wu MS, Lee TC, Chen HP, Wu CY. Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J Clin Gastroenterol 2013; 47: e55-59.
11. Shen Z, Chen B, Hou X, Chen P, Zhao G, Fan J. Polymorphism-433 C>T of the Osteopontin Gene is Associated with the Susceptibility to Develop Gliomas and their Prognosis in a Chinese Cohort. Cell Physiol Biochem 2014; 34: 1190-1198.
12. Chen Y, Liu H, Wu W, Li Y, Li J. Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res 2013; 32: 45.
13. Wang JL, Nong LG, Tang YJ, Wei YS, Yang FL, Wang CF. Correlation between OPN gene polymorphisms and the risk of nasopharyngeal carcinoma. Med Oncol 2014; 31: 20.
14. Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, Kao SY. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol 2010; 46: 302-306.
15. Wang J, Nong L, Wei Y, Qin S, Zhou Y, Tang Y. Association of osteopontin polymorphisms with nasopharyngeal carcinoma risk. Hum Immunol 2014; 75: 76-80.
16. Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G. Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer 2012; 12: 477.
17. Mu G, Wang H, Cai Z, Ji H. OPN-443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort. Cell Physiol Biochem 2013; 32: 171-179.
18. Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, Dear AE, Palmer LJ, Norman PE. Association Between Osteopontin and Human Abdominal Aortic Aneurysm. Arterioscler Thromb Vasc Biol 2007; 27: 655-660.
19. Xu Q, Yuan B, Xue F, Zhang L, Li J, Guo H, Yue T. OPN gene polymorphisms are associated with susceptibility and clinicopatholigical characteristics of cervical cancer in a Chinese cohort. Cancer Biomark 2011; 10: 233-239.
20. Chen J, Wu Q, Lu Y, Xu T, Huang Y, Ribas J, Ni X, Hu G, Huang F, Zhou L, Lu D. SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J Hum Genet 2010; 55: 456-461.
21. Giacopelli F. Polymorphisms in the osteopontin promoter affect its transcriptional activity Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004; 20: 87-96.
22. Chu M, Yang P, Hou S, Li F, Chen Y, Kijlstra A. Behcet's disease exhibits an increased osteopontin serum level in active stage but no association with osteopontin and its receptor gene polymorphisms. Hum Immunol 2011; 72: 525.